NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …
There is a much-quoted statistic, which has become so hackneyed that it's largely ignored these days, but while you are …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

